Erratum

Following the publication of the Clinical Trial Report by Sten Madsbad ‘Liraglutide Effect and Action in Diabetes (LEAD™) trial’, published in the March 2009 issue of Expert Review of Endocrinology and Metabolism (Expert Rev. Endocrinol. Metab. 4[2], 119–129 [2009]), it has been brought to our attention that a result in the table ‘Main results from the LEAD 5 study’ on page 126 was incorrectly printed as:

Table 6. Main results from the LEAD 5 study.

Parameter	Metformin + glimepiride + liraglutide (1.8 mg/day)	Metformin + glimepiride + placebo	Metformin + glimepiride + insulin glargine
Glycemia
Weight change (kg)	-1.8*^‡	-0.4	-1.6

^*p < 0.05 versus metformin + glimepiride + placebo.

^‡p < 0.05 versus metformin + glimepiride + glagine.

FPG: Fasting plasma glucose; Hb_A1c: Glycated hemoglobin; LEAD: Liraglutide Effect and Action in Diabetes.

The correct table is shown below:

Table 6. Main results from the LEAD 5 study.

Parameter	Metformin + glimepiride + liraglutide (1.8 mg/day)	Metformin + glimepiride + placebo	Metformin + glimepiride + insulin glargine
Glycemia
Weight change (kg)	-1.8*^‡	-0.4	1.6

^*p < 0.05 versus metformin + glimepiride + placebo.

^‡p < 0.05 versus metformin + glimepiride + glagine.

FPG: Fasting plasma glucose; Hb_A1c: Glycated hemoglobin; LEAD: Liraglutide Effect and Action in Diabetes.

The authors and editors of Expert Review of Endocrinology and Metabolism would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.